Cybin CEO to Discuss Next-Generation Mental Health Treatments at Canaccord Genuity Conference

Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN), a leader in the development of next-generation mental health treatments, has announced that its CEO, Doug Drysdale, will engage in a fireside chat at the prestigious Canaccord Genuity 45th Annual Growth Conference. Scheduled for August 12, 2025, in Boston, this event will spotlight Cybin's groundbreaking work in neuropsychiatry, particularly its development of psychedelic-based therapies for mental health conditions.

The live webcast of the chat, set for 2:30 p.m. ET, will be accessible to a global audience, with an archived version available on Cybin's investor relations site. This participation underscores Cybin's commitment to addressing the significant unmet needs in mental healthcare through innovative treatments like CYB003 and CYB004, currently in advanced clinical trials for major depressive disorder and generalized anxiety disorder, respectively.

Cybin's research pipeline, focused on 5-HT-receptor compounds, represents a promising frontier in mental health treatment. The company's efforts to develop intermittent treatments that offer long-lasting results could revolutionize the way mental health conditions are managed, providing hope to millions worldwide. For more details on Cybin's initiatives, visit https://www.cybin.com.

The implications of Cybin's work extend beyond the scientific community, offering potential economic and social benefits by reducing the burden of mental health conditions on healthcare systems and improving quality of life for patients. The company's presence at the Canaccord Genuity conference is a testament to the growing recognition of psychedelic compounds as viable treatment options in mainstream medicine.

For investors and stakeholders interested in following Cybin's progress, updates are regularly posted in the company's newsroom at https://ibn.fm/CYBN. Cybin's participation in this high-profile event not only highlights its leadership in the psychedelic and mental health sectors but also signals the increasing acceptance and potential of psychedelic therapies in addressing complex mental health challenges.